ROIV vs. VKTX, LEGN, CTLT, ASND, CERE, JAZZ, ITCI, CYTK, ELAN, and BPMC
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Viking Therapeutics (VKTX), Legend Biotech (LEGN), Catalent (CTLT), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Elanco Animal Health (ELAN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Roivant Sciences (NASDAQ:ROIV) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
Roivant Sciences has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Roivant Sciences currently has a consensus target price of $16.90, indicating a potential upside of 51.57%. Viking Therapeutics has a consensus target price of $112.25, indicating a potential upside of 57.83%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Roivant Sciences.
64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 4.6% of Roivant Sciences shares are owned by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Viking Therapeutics had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for Viking Therapeutics and 2 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.43 beat Viking Therapeutics' score of 0.89 indicating that Roivant Sciences is being referred to more favorably in the media.
Viking Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Viking Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Roivant Sciences has a net margin of 3,624.14% compared to Viking Therapeutics' net margin of 0.00%. Viking Therapeutics' return on equity of -18.41% beat Roivant Sciences' return on equity.
Viking Therapeutics received 555 more outperform votes than Roivant Sciences when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 75.00% of users gave Roivant Sciences an outperform vote.
Summary
Viking Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
